← Erland Erdmann

Papers by Erland Erdmann

Page 1 · newest first

1. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet · 2005
2. Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant HypertensionJournal of the American College of Cardiology · 2012
3. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failureEuropean Heart Journal · 2007
4. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure†European Heart Journal · 2012
5. Multicentre, Randomized, Double-Blind, Prospective Study on the Effects of ImmunoAdSorptiOn on Cardiac Function in Patients with Dilated CardioMyopathy (IASO-DCM): Rationale and DesignEuropean Journal of Heart Failure · 2024
6. Effect of adaptive servo ventilation on central sleep apnea and sleep structure in systolic heart failure patients: polysomnography data from the SERVE‐HF major sub studyJournal of Sleep Research · 2022
7. Heart rate at discharge in patients with acute decompensated heart failure is a predictor of mortalityEuropean journal of medical research · 2020
8. Biomarkers in Patients with Heart Failure and Central Sleep Apnoea: Findings From the SERVE-HF TrialESC Heart Failure · 2020
9. Association of serious adverse events with Cheyne–Stokes respiration characteristics in patients with systolic heart failure and central sleep apnoea: A SERVE‐Heart Failure substudy analysisRespirology · 2019
10. Mini Review on: Simple, Practical, and Evidence-Based - an Algorithm for The Diagnosis and Treatment of Iron DeficiencyJournal of Cardiology and Cardiovascular Sciences · 2018
11. Adaptive Servo-Ventilationf for Central Sleep Apnoea in Systolic Heart Failure: Results of the Major Substudy of SERVE-HFEuropean Journal of Heart Failure · 2017
12. Phenotyping of Sleep‐Disordered Breathing in Patients With Chronic Heart Failure With Reduced Ejection Fraction—the SchlaHF RegistryJournal of the American Heart Association · 2017
13. Adaptive servo ventilation for central sleep apnoea in heart failure: SERVE-HF on-treatment analysisEuropean Respiratory Journal · 2017
14. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart FailureNew England Journal of Medicine · 2015
15. Sleep-disordered Breathing in Heart Failure – Current State of the ArtCardiac failure review · 2015
16. Determining the prevalence and predictors of sleep disordered breathing in patients with chronic heart failure: rationale and design of the SCHLA-HF registryBMC Cardiovascular Disorders · 2014
17. Observational follow‐up of the PROactive study: a 6‐year updateDiabetes Obesity and Metabolism · 2013
18. Rationale and Design of the SERVE-HF Study: Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnoea with Adaptive Servo-Ventilation in Patients with Chronic Heart FailureEuropean Journal of Heart Failure · 2013
19. Ischemic Preconditioning for Prevention of Contrast Medium–Induced NephropathyCirculation · 2012
20. Cinaciguat, a Soluble Guanylate Cyclase Activator: Results from the Randomized, Controlled, Phase IIb COMPOSE Programme in Acute Heart Failure SyndromesEuropean Journal of Heart Failure · 2012
21. Long-Term Mortality with Cardiac Resynchronization Therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) TrialEuropean Journal of Heart Failure · 2012
22. Clinical Impact of Atrial Fibrillation in Patients with Pulmonary HypertensionPLoS ONE · 2012
23. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemiaEuropean Respiratory Journal · 2011
24. High‐density lipoprotein‐cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactiveDiabetes Obesity and Metabolism · 2011
25. Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive studyDiabetic Medicine · 2011
26. Association and Prognostic Impact of Heart Rate and Micro- Albuminuria in Patients with Type 2 Diabetes and Cardiovascular Disease: Results from the PROactive TrialJournal of Atherosclerosis and Thrombosis · 2011
27. Informed Consent Prior to Coronary Angiography in a Real World Scenario: What Do Patients Remember?PLoS ONE · 2010
28. Beta1-Adrenoceptor Polymorphism Predicts Flecainide Action in Patients with Atrial FibrillationPLoS ONE · 2010
29. Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin–angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)Journal of Diabetes · 2010
30. Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III TrialCardiovascular Therapeutics · 2010
31. Improved Survival with Bisoprolol in Patients with Heart Failure and Renal Impairment: An Analysis of the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) TrialEuropean Journal of Heart Failure · 2010
32. NT‐pro‐BNP predicts worsening renal function in patients with chronic systolic heart failureInternal Medicine Journal · 2010
33. Pioglitazone and mechanisms of CV protectionQJM · 2009
34. Continuous Central Haemodynamic Measurements During the Six-Minute Walk Test and Daily Life in Patients with Chronic Heart FailureEuropean Journal of Heart Failure · 2009
35. Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspectiveCost Effectiveness and Resource Allocation · 2009
36. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss settingSwiss Medical Weekly · 2009
37. Safety and tolerability of beta-blockers: prejudices and realityEuropean Heart Journal Supplements · 2009
38. Differential effects of red and white wines on inhibition of the platelet-derived growth factor receptor: impact of the mash fermentationCardiovascular Research · 2008
39. The Effect of Positive Inotropes on the Failing Human MyocardiumCardiology · 2008
40. Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator–Activated Receptor γ in Cardiac FibrosisDiabetes · 2008
41. Prognostic Impact of NT-proBNP and Renal Function in Comparison to Contemporary Multi-Marker Risk Scores in Heart Failure PatientsEuropean Journal of Heart Failure · 2008
42. Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney DiseaseJournal of the American Society of Nephrology · 2007
43. An increase in HbA1c after percutaneous coronary intervention raises the risk for restenosis in patients without Type 2 diabetes mellitusDiabetic Medicine · 2007
44. Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular DiseaseDiabetes Care · 2007
45. Review: Statin plus thiazolidinedione use in patients with diabetes at high cardiovascular riskThe British Journal of Diabetes · 2007
46. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)European Heart Journal Supplements · 2007
47. Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safetyEP Europace · 2007
48. Effect of Cardiac Resynchronization on Morbidity and Mortality of Diabetic Patients With Severe Heart FailureDiabetes Care · 2007
49. Modification of surface antigens in blood CD8+ T-lymphocytes in COPD: effects of smokingEuropean Respiratory Journal · 2006
50. Effect of Cardiac Resynchronization on the Incidence of Atrial Fibrillation in Patients With Severe Heart FailureCirculation · 2006